Abstract
Noonan syndrome (NS) is a group of inherited autosomal dominant diseases characterized by a disturbance of the RAS-MAPK signaling pathway and leading to various clinical manifestations. The prevalence in the world is estimated at 1–2 per 20 000 newborns. The review discusses the molecular genetic causes of the disease, the characteristics of the clinical manifestations of the disease, and the methods of molecular genetic diagnosis.
Similar content being viewed by others
REFERENCES
Tartaglia, M., Kalidas, K., Shaw, A., et al., PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype—phenotype correlation, and phenotypic heterogeneity, Am. J. Hum. Genet., 2002, vol. 70, pp. 1555—1563.
Noonan, J.A., Hypertelorism with Turner phenotype: a new syndrome with associated congenital heart disease, Am. J. Dis. Child., 1968, vol. 116, pp. 373—380.
Celermajer, J.M., Bowdler, J.D., and Cohen, D.H., Pulmonary stenosis in patients with the Turner phenotype in the male, Am. J. Dis. Child., 1968, vol. 116, pp. 351—358.
Nora, J.J., Nora, A.H., Sinha, A.K., et al., The Ullrich—Noonan syndrome (Turner phenotype), Am. J. Dis. Child., 1974, vol. 127, pp. 48—55.
Tartaglia, M., Mehler, E.L., Goldberg, R., et al., Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome, Nat. Genet., 2001, vol. 29, pp. 465—468.
Romano, A.A., Allanson, J.E., Dahlgren, J., et al., Noonan syndrome: clinical features, diagnosis, and management guidelines, Pediatrics, 2010, vol. 126, pp. 746—759. https://doi.org/10.1542/peds.2009-3207
Tartaglia, M., Zampino, G., and Gelb, B.D., Noonan syndrome: clinical aspects and molecular pathogenesis, Mol. Syndromol., 2010, vol. 1, pp. 2—26. https://doi.org/10.1159/000276766
Lepri, F.R., Scavelli, R., Digilio, M.C., et al., Diagnosis of Noonan syndrome and related disorders using target next generation sequencing, BMC Med. Genet., 2014, vol. 15, p. 14. https://doi.org/10.1186/1471-2350-15-14
Tidyman, W.E. and Rauen, K.A., The RASopathies: developmental syndromes of RAS/MAPK pathway dysregulation, Curr. Opin. Genet. Dev., 2009, vol. 19, pp. 230—236.
Bezniakow, N. and Gos, M.O.E., The rasopathies as an example of RAS/MAPK pathway disturbances—clinical presentation and molecular pathogenesis of selected syndromes, Dev. Period. Med., 2014, vol. 18, pp. 285—296.
Schubbert, S., Shannon, K., and Bollag, G., Hyperactive RAS in developmental disorders and cancer, Nat. Rev. Cancer, 2007, vol. 7, pp. 295—308.
van der Burgt, I., Berends, E., Lommen, E., et al., Clinical and molecular studies in a large Dutch family with Noonan syndrome, Am. J. Med. Genet., 1994, vol. 53, pp. 187—191.
Yoshida, R., Hasegawa, T., Hasegawa, Y., et al., Protein—tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome, J. Clin. Endocrinol. Metab., 2004, vol. 89, pp. 3359—3364.
Zenker, M., Buheitel, G., Rauch, R., et al., Genotype—phenotype correlations in Noonan syndrome, J. Pediatr., 2004, vol. 144, pp. 368—374.
Jongmans, M., Otten, B., Noordam, K., et al., Genetics and variation in phenotype in Noonan syndrome, Horm. Res., 2004, vol. 62, suppl. 3, pp. 56—59.
Bhambhani, V. and Muenke, M., Noonan syndrome, Am. Fam. Physician, 2014, vol. 89, pp. 37—43.
Gelb, B.D. and Tartaglia, M., Noonan syndrome with multiple lentigines, GeneReviews NCBI, 1993.
Abdel-Salam, E. and Temtamy, S.A., Familial Turner phenotype, J. Pediatr., 1969, vol. 74, pp. 67—72.
Maximilian, C., Ioan, D.M., and Fryns, J.P., A syndrome of mental retardation, short stature, craniofacial anomalies with palpebral ptosis and pulmonary stenosis in three siblings with normal parents: an example of autosomal recessive inheritance of the Noonan phenotype? Genet. Couns., 1992, vol. 3, pp. 115—118.
van Der Burgt, I. and Brunner, H., Genetic heterogeneity in Noonan syndrome: evidence for an autosomal recessive form, Am. J. Med. Genet., 2000, vol. 94, pp. 46—51.
Roberts, A.E., Allanson, J.E., Tartaglia, M., et al., Noonan syndrome, Lancet, 2013, vol. 381, pp. 333—342. https://doi.org/10.1016/S0140-6736(12)61023-X
Jorge, A.A.L., Malaquias, A.C., Arnhold, I.J.P., et al., Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway, Horm. Res., 2009, vol. 71, pp. 185—193.
Zenker, M., Lehmann, K., Schulz, A.L., et al., Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations, J. Med. Genet., 2007, vol. 44, pp. 131—135.
Kratz, C.P., Zampino, G., Kriek, M., et al., Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations, Am. J. Med. Genet, Part A, 2009, vol. 149A, pp. 1036—1040.
Friday, B.B. and Adjei, A.A., K-ras as a target for cancer therapy, Biochim. Biophys. Acta, 2005, vol. 1756, pp. 127—144.
Plowman, S.J., Williamson, D.J., O’Sullivan M.J., et al., While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable, Mol. Cell Biol., 2003, vol. 23, pp. 9245—9250.
Zenker, M., Horn, D., Wieczorek, D., et al., SOS1 is the second most common Noonan gene, but plays no major role in cardio-facio-cutaneous syndrome, J. Med. Genet., 2007, vol. 44, pp. 651—656.
Tartaglia, M., Pennacchio, L.A., Zhao, C., et al., Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome, Nat. Genet., 2007, vol. 39, pp. 75—79.
Pierpont, E.I., Pierpont, M.E., Mendelsohn, N.J., et al., Genotype differences in cognitive functioning in Noonan syndrome, Genes Brain Behav., 2009, vol. 8, pp. 275—282.
Egan, S.E. and Weinberg, R.A., The pathway to signal achievement, Nature, 1993, vol. 365, pp. 781—783.
Takai, Y., Sasaki, T., and Matozaki, T., Small GTP-binding proteins, Physiol. Rev., 2001, vol. 81, pp. 153—208.
Roberts, A.E., Araki, T., Swanson, K.D., et al., Germline gain-of-function mutations in SOS1 cause Noonan syndrome, Nat. Genet., 2007, vol. 39, pp. 70—74.
Lepri, F., De Luca, A., Stella, L., et al., SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype—phenotype correlations, Hum. Mutat., 2011, vol. 32, pp. 760—772.
Wellbrock, C., Karasarides, M., and Marais, R., The RAF proteins take centre stage, Nat. Rev. Mol. Cell Biol., 2004, vol. 5, pp. 875—885.
Leicht, D.T., Balan, V., Kaplun, A., et al., Raf kinases: function, regulation and role in human cancer, Biochim. Biophys. Acta, 2007, vol. 1773, pp. 1196—1212.
Cirstea, I.C., Kutsche, K., Dvorsky, R., et al., A restricted spectrum of NRAS mutations causes Noonan syndrome, Nat. Genet., 2010, vol. 42, pp. 27—29.
Denayer, E., Peeters, H., Sevenants, L., et al., NRAS mutations in Noonan syndrome, Mol. Syndromol., 2012, vol. 3, pp. 34—38.
Sarkozy, A., Carta, C., Moretti, S., et al., Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum, Hum. Mutat., 2009, vol. 30, pp. 695—702.
Nystrom, A.M., Ekvall, S., Berglund, E., et al., Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders, J. Med. Genet., 2008, vol. 45, pp. 500—506.
Aoki, Y., Niihori, T., Banjo, T., et al., Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome, Am. J. Hum. Genet., 2013, vol. 93, pp. 173—180.
Yamamoto, G.L., Aguena, M., Gos, M., et al., Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome, J. Med. Genet., 2015, vol. 52, pp. 413—421.
Wang, D.Z., Hammond, V.E., Abud, H.E., et al., Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for Sos1 in EGFR signaling and development, Genes Dev., 1997, vol. 11, pp. 309—320.
Johnston, J.J., van der Smagt, J.J., Rosenfeld, J.A., et al., Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants, Genet. Med., 2018, pp. 1—11. https://doi.org/10.1038/gim.2017.249
Nisbet, D.L., Griffin, D.R., and Chitty, L.S., Prenatal features of Noonan syndrome, Prenat. Diagn., 1999, vol. 19, pp. 642—647.
Maheshwari, M., Belmont, J., Fernbach, S., et al., PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13, Hum. Mutat., 2002, vol. 20, pp. 298—304.
Tafazoli, A., Eshraghi, P., Koleti, Z.K., et al., Noonan syndrome—a new survey, Arch. Med. Sci., 2017, vol. 13, pp. 215—222.
Hafner, C. and Groesser, L., Mosaic RASopathies, Cell Cycle, 2013, vol. 12, pp. 43—50.
Siegel, D.H., McKenzie, J., Frieden, I.J., et al., Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome, Br. J. Dermatol., 2011, vol. 164, pp. 521—529.
Rauen, K.A., NIH public access, Annu. Rev. Genomics Hum. Genet., 2013, pp. 355—369.
Gripp, K.W. and Lin, A.E., Costello syndrome, GeneReviews NCBI, 1993. https://www.ncbi.nlm.nih.gov/books/NBK1507/.
Smith, L.P., Podraza, J., and Proud, V.K., Polyhydramnios, fetal overgrowth, and macrocephaly: prenatal ultrasound findings of Costello syndrome, Am. J. Med. Genet., Part A, 2009, vol. 149A, pp. 779—784.
Siegel, D.H., Mann, J.A., Krol, A.L., et al., Dermatological phenotype in Costello syndrome: consequences of RAS dysregulation in development, Br. J. Dermatol., 2012, vol. 166, pp. 601—607.
Boyd, K.P., Korf, B.R., and Theos, A., Neurofibromatosis type 1, J. Am. Acad. Dermatol., 2009, vol. 61, pp. 1—6.
Friedman, J.M., Neurofibromatosis 1, GeneReviews NCBI, 1993. https://www.ncbi.nlm.nih.gov/books/ NBK1109/.
Abramowicz, A. and Gos, M., Neurofibromin in neurofibromatosis type 1—mutations in NF1gene as a cause of disease, Dev. Period Med., 2014, vol. 18, pp. 297—306.
Curto, M. and McClatchey, A.I., Nf2/Merlin: a coordinator of receptor signalling and intercellular contact, Br. J. Cancer, 2008, vol. 98, pp. 256—262.
Writzl, K., Hoovers, J., Sistermans, E.A., et al., LEOPARD syndrome with partly normal skin and sex chromosome mosaicism, Am. J. Med. Genet., Part A, 2007, vol. 143A, pp. 2612—2615.
Tartaglia, M., Gelb, B.D., and Zenker, M., Noonan syndrome and clinically related disorders, Best Pract. Res. Clin. Endocrinol. Metab., 2011, vol. 25, pp. 161—179.
https://portal.biobase-international.com/hgmd/pro/.
Funding
This work was performed as part of the state task of the Ministry of Education and Science of Russia.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that they have no conflict of interest. This study does not contain any research involving humans or animals as research objects.
Rights and permissions
About this article
Cite this article
Orlova, A.A., Dadali, E.L. & Polyakov, A.V. Clinical and Genetic Characteristics of Noonan Syndrome and Noonan-like Diseases. Russ J Genet 56, 540–547 (2020). https://doi.org/10.1134/S1022795420050117
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1022795420050117